Chemokines and chemokine receptors: Large and small therapeutic strategies for inflammatory diseases

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 381-388

  Das, Anuk M ^a   Brodmerkel, Carrie M ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; ABN 912; ABX IL 8 MONOCLONAL ANTIBODY; APLAVIROC; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; CP 481715; EOTAXIN; G PROTEIN COUPLED RECEPTOR; INCB 3284; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; MARAVIROC; METHOTREXATE; MK 0812; MLN 1202; MLN 3701; MLN 3897; MONOCYTE CHEMOTACTIC PROTEIN 1; PS 938285; SCH 527123; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; ATHEROSCLEROSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG POTENCY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; LIGAND BINDING; LIVER TOXICITY; MULTIPLE SCLEROSIS; NEUTROPHILIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRODUCT DEVELOPMENT; PROTEIN FAMILY; PROTEIN FUNCTION; PSORIASIS; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS;

EID: 33751194437     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.07.003     Document Type: Review

References (58)

1. Charo I.F., and Ransahoff R.M. The many roles of chemokine and chemokine receptors in inflammation. NEJM 354 (2006) 610-621
2. Wells T.N.C., et al. Chemokine blockers - therapeutics in the making?. Trends Pharmacol. Sci. 27 (2006) 41-47
3. Baumann A. Early development of therapeutic biologics-pharmacokinetics. Curr. Drug Metab. 7 (2006) 15-21
4. Redfern W.S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58 (2003) 32-45
5. Power C.A. Knock out models to dissect chemokine receptor function in vivo. J. Immunol. Methods 273 (2003) 73-82
6. Peters W., et al. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. 98 (2001) 7958-7963
7. Del Rio L., et al. CXCR2 deficiency confers imparied neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J. Immunol. 167 (2001) 6503-6509
8. Machado F.S., et al. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J. Infect. Dis. 191 (2005) 627-636
9. Muikaida N., et al. Inhibition of neutrophil-mediated actute inflammatory injury by an antibody against interleukin-8 (IL-8). Inflamm. Res. 47 (1998) s151-s157
10. Nocker R.E., et al. Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol. 109 (1996) 183-191
11. Wang N., et al. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J. Biol. Chem. 271 (1996) 8837-8842
12. Huang S., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161 (2002) 125-134
13. Horowitz M.H., and Krueger G.G. ABX-IL8 in the treatment of psoriasis: clinical results. Society Invest. Derm. 119 (2002) Abstract 188
14. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
15. Lutgens E., et al. Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation 111 (2005) 3443-3452
16. Chen A., et al. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes. Res. 13 (2005) 1311-1320
17. Weisberg S.P., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 116 (2006) 115-124
18. Ogata H., et al. The role of monocyte chemoattractant protein-1 in the pathogenesis of collagen-induced arthritis in rats. J. Pathol. 182 (1997) 106-114
19. Brodmerkel C.M., et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J. Immunol. 15 (2005) 5370-5378
20. Moore B.B., et al. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am. J. Respir. Cell Mol. Biol. (2006). http://www.ajrcmb.org/ 10.1165/rcmb.2005-023900
21. Anders H.J., et al. Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int. 69 (2006) 29-32
22. Gao W., et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic allograft rejection. J. Clin. Invest. 105 (2000) 35-44
23. Revesz L., et al. Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis. Bioorg. Med. Chem. Lett. 15 (2005) 5160-5164
24. Pease J.E., and Horuk R. CCR1 antagonists in clinical development. Exp. Opin. Investig. Drugs 14 (2005) 785-796
25. Miller A.L., et al. Deletion of CCR1 attenuates pathophysiologic responses during respiratory syncytial virus infection. J. Immunol. 176 (2006) 2562-2567
26. Post T.W., et al. Molecular characterization of two murine eosinophil beta chemokine receptors. J. Immunol. 155 (1995) 5299-5305
27. Gao J.L., et al. Identification of a mouse eosinophil receptor for the CC chemokine eotaxin. Biochem. Biophys. Res. Commun. 223 (1996) 679-684
28. Combadiere C., Ahuja S.K., and Murphy P.M. Cloning and functional expression of a human eosinophil CC chemokine receptor. J. Biol. Chem. 270 (1996) 16491-16494
29. Pease J.E. Asthma, allergy, and chemokines. Curr. Drug Targets 7 (2006) 3-12
30. Leckie M.J., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
31. Flood-Page P.T., et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthamatic airway. Am. J. Respir. Crit. Care Med. 167 (2003) 199-204
32. Fryer A.D., et al. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J. Clin. Invest. 116 (2006) 228-236
33. Morokata T., et al. A novel, selective, and orally available antagonist for CC chemokine receptor 3. J. Pharmacol. Exp. Ther. 317 (2006) 244-250
34. Suzuki K., et al. In Vitro and in vivo characterization of a novel CCR3 anatagonist, YM-344031. Biochem. Biophys. Res. Commun. 339 (2006) 1217-1223
35. Dent G., et al. Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am. J. Respir. Crit. Care Med. 169 (2004) 1110-1117
36. Deng H., et al. Identification of a major co-receptor for priamry isolates of HIV-1. Nature 381 (1996) 647-648
37. Liu R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
38. Vierboom M.P., et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular wieght antagonist of CCR5. Arthritis Rheum. 52 (2005) 627-636
39. Gao W., et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 72 (2005) 1199-1205
40. Roschke V., et al. Characterization of novel human monoclonal antibodies that specifically antagonize CCR5 and block HIV-1 entry. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2005) (Abstract 2871)
41. Strieter R.M., et al. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 16 (2005) 593-609
42. Romagnani P., et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on Th1 or Th2 cytokine production. J. Allergy Clin. Immunol. 116 (2005) 1372-1379
43. Ray N., and Doms R.W. HIV-1 coreceptors and their inhibitors. Curr. Top Microbiol. Immunol. 303 (2006) 97-120
44. Pistoia V., et al. Lymphoproliferative disorders and chemokines. Curr. Drug Targets 7 (2006) 81-90
45. Nanki T., et al. Stromal-cell derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis. J. Immunol. 165 (2000) 6590-6598
46. Fruehauf S., and Seeger T. New strategies for mobilization of hematopoietic stem cells. Future Oncol. 1 (2005) 375-383
47. Pelus L.M., et al. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Exp. Hematol. 33 (2005) 295-307
48. Rubin J.B., et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. PNAS 100 (2003) 13513-13518
49. Liang Z., et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 65 (2005) 967-971
50. Tamamura H. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett 569 (2004) 99-104
51. De Klerck B. Pro-inflammatorry properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res. Ther. 7 (2005) R1208-R1220
52. Zou Y.-R., et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393 (1998) 595-599
53. Nagasawa T., et al. Defects of B-cell lymphopoiesis and bone marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382 (1996) 635-638
54. Heydtmann M., et al. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangocyte and hepatocytes within the inflamed human liver. J. Immunol. 174 (2005) 1055-1062
55. Ishikawa S., et al. Aberrant high expression of B lymphocyte chemokine (BLC/CXC:13) by C11b+CX11c+ deneritic cells in murine lupus and preferential chemotaxis of B1 cell toward BLC. J. Exp. Med. 193 (2001) 1393-1402
56. Cambridge G., and Edwards J.C. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6 (2006) 394-403
57. Gladue R.P., et al. The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. J. Immunol. 176 (2006) 3141-3148
58. Ding, et al. Bertilimumab Cambridge Antibody Technology Group. Curr. Opin. Investig. Drugs 5 (2004) 1213-1218